ZIA CP010121-02035 (ZIA) | |||
---|---|---|---|
Title | Biomarkers of benzene exposure | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Rothman, Nat | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $57,383 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Leukemia (66.0%) Non Hodgkins Lymphoma (34.0%) |
||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
"""Although benzene is an established human leukemogen, it still remains an imrtant industrial chemical (>2 billion ponds produced annually in U.S.) and a componenet of unleaded gasoline. The health risk posed by occupational exposure to relatively low levels of benzene (i.e., <10 ppm), or by the substantially lower environmental exosures experienced by essentially the entire populations, is uncertain and controversial. Results from the NCI-Chinese Academy of Preventive Medicine retrospective cohort study of benzene exosure in China suggest that there is risk of hematologic malignancy in workers exposed to <10 ppm. This remains an important research question because China is considering lowering its current enzene standard of 13 ppm and there is ongoing concern in the United States and Europe about risk frombenzene exposure at or below the current standard of 1 ppm. This cross-sectional study of early effect biomarkers exposed to benzene levels from 0.5 to > 10 ppm seeks to provide understanding of benzene?s effects at low levels of exposure.""" |